Fusion Polypeptide Vaccine Composition for Broad Streptococcus suis Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against Streptococcus suis infections are not effective due to the large number of serotypes, variation in virulence among strains, and limited understanding of virulence factors, leading to serotype-specific protection and potential loss of efficacy with mutations.
Innovation Solution
Development of immunogenic compositions and vaccine compositions comprising fusion polypeptides made up of fragments from multiple virulence factors, including zinc-binding proteins, proteases, nucleotidases, and proteins with an LPXTG-motif, which induce broad antibody responses and are transferred to piglets via colostrum, reducing S. suis symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines are developed targeting specific virulence factors of Streptococcus suis, then protective efficacy against specific strains is improved, but adaptability to different serotypes and mutant strains deteriorates
Solution Approach 1:
The vaccine composition uses fusion polypeptides that combine multiple virulence factor fragments (capsule polysaccharide antigens, cell wall proteins, surface proteins) into single molecular entities. This multi-functional design allows the vaccine to target multiple serotypes and strains simultaneously, providing universal protection against diverse S. suis infections while maintaining high protective efficacy.
Solution Approach 2:
The invention creates composite antigen structures by fusing fragments from different virulence factors (e.g., capsule polysaccharide antigens with cell wall proteins) into chimeric polypeptides. These composite antigens elicit broader immune responses that cover multiple serotypes and mutant strains, resolving the contradiction between specific protection and broad adaptability.
2Adaptability or versatility
If whole cell vaccine preparations are used, then broad coverage against multiple serotypes is improved, but manufacturing complexity and unwanted reactions increase
Solution Approach 1:
The invention extracts and isolates only the essential virulence factor fragments (capsule polysaccharide antigens, cell wall proteins, surface proteins) from whole bacteria, removing unnecessary cellular components. This extraction approach maintains broad serotype coverage through multiple antigen targets while dramatically simplifying manufacturing by producing only the immunogenic essentials through recombinant expression.
Solution Approach 2:
The vaccine design segments the complex whole cell vaccine into discrete functional components (fusion polypeptides containing specific virulence factor fragments). Each fusion polypeptide is a controlled, defined segment that can be independently produced and characterized, reducing manufacturing complexity while maintaining broad protective coverage.
3Ease of manufacture
If single antigen vaccines are used, then manufacturing simplicity is improved, but reliability against mutant strains deteriorates
Solution Approach 1:
The invention merges multiple virulence factor fragments from different antigen sources into fusion polypeptides. Each fusion polypeptide combines fragments such as capsule polysaccharide antigens, cell wall proteins, and surface proteins into a single chimeric molecule. This merging approach maintains manufacturing simplicity (single recombinant expression system) while ensuring reliability against mutant strains through multi-epitope coverage.
Data Source
AI summary
The present disclosure relates to immunogenic fusion polypeptides, immunogenic compositions and vaccine compositions comprising said fusion polypeptides and use thereof for immunization of mammals susceptible to Streptococcus suis infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.